BioSig Technologies Secures $10M Financing

Ticker: STEX · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1530766

Biosig Technologies, Inc. 8-K Filing Summary
FieldDetail
CompanyBiosig Technologies, Inc. (STEX)
Form Type8-K
Filed DateJun 26, 2024
Risk Levelmedium
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: financing, debt, medical-device

TL;DR

BioSig just closed a $10M debt deal with Lyra Capital, maturing in 2027.

AI Summary

On June 24, 2024, BioSig Technologies, Inc. announced the closing of a $10 million senior secured note financing with an affiliate of Lyra Capital. The notes mature on June 24, 2027, and bear interest at a rate of 12% per annum. This financing is intended to support BioSig's ongoing operations and strategic initiatives.

Why It Matters

This $10 million financing provides BioSig Technologies with crucial capital to fund its operations and pursue strategic growth opportunities, potentially impacting its ability to develop and commercialize its medical device technology.

Risk Assessment

Risk Level: medium — The company has taken on new debt, which increases financial leverage and introduces interest payment obligations.

Key Numbers

  • $10 million — Financing Amount (Capital raised from Lyra Capital)
  • 12% — Interest Rate (Annual interest on the notes)
  • 3 years — Maturity Term (Duration of the financing)

Key Players & Entities

  • BioSig Technologies, Inc. (company) — Registrant
  • Lyra Capital (company) — Financing Partner
  • $10 million (dollar_amount) — Financing Amount
  • June 24, 2024 (date) — Financing Closing Date
  • June 24, 2027 (date) — Note Maturity Date

FAQ

What is the purpose of the $10 million financing?

The financing is intended to support BioSig's ongoing operations and strategic initiatives.

Who is the lender for this financing?

The financing was provided by an affiliate of Lyra Capital.

When do the notes mature?

The notes mature on June 24, 2027.

What is the interest rate on the notes?

The notes bear interest at a rate of 12% per annum.

What type of financing is this?

This is a senior secured note financing.

Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 12.7 · Accepted 2024-06-26 16:40:13

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share BSGM The NASDAQ Capital M

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOSIG TECHNOLOGIES, INC. Date: June 26, 2024 By: /s/ Anthony Amato Name: Anthony Amato Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.